Background
Methods
-
IMT of the carotid, at month 18, i.e. six months after the end of the treatment,
-
the IMT of the right humeral artery,
-
the arterial stiffness through the pulse wave velocity (PWV),
-
and arterial distensibility through diameter change over cardiac cycle,
-
the degree of aortic and renal artery stenosis,
-
the 24-hour mean systolic (SBP) and diastolic (DBP) blood pressure, twelve months after onset of the treatment.
Participants
Intervention
Outcomes
-
the CCA IMT six months after the end of the treatment,
-
the arterial stiffness, measured by carotid-radial pulse wave velocity and carotid-femoral pulse wave velocity. Using Pulse Pen®, Sphygmocor®, or Complior® (depending on the availability of the device) in motionless children, two captors were positioned, one on CCA and another on the homo-lateral femoral artery. Pulse wave velocity expressed in meter/second (m/s) corresponds to the measurement of the distance divided by the transit time between the two captors. Distensibility was calculated on CCA and on the humeral artery from = (systolic diameter – diastolic diameter)/ diastolic diameter, measured by ultrasound),
-
the arterial distensibility has been calculated with the diameter change over cardiac cycle indexed on the blood pressure level,
-
the supra-valvular and renal stenosis, measured by bidimensional ultrasound and doppler parameters of cardiac and right renal artery at the start, after 12 and 18 months,
-
the arterial blood pressure measured by 24-H ambulatory blood pressure monitoring before and at the end of 12-month treatment period on the non-dominant arm. An ambulatory device with the appropriate cuff size suitable for use in children measured the blood pressure every 20 minutes during the day and every hour during the night, automatic night time division was set at 10 PM to 7 AM. Parents filled out a diary indicating the physical activity, and sleep time during 24hours. The minimum, maximum, mean, systolic and diastolic blood pressures were measured. BP load was calculated as the proportion of readings above a threshold of the pediatric 95th percentile during 24H awake and sleep periods.
Harms
Sample size
Blinding
Data monitoring committee (DMC)
Statistics
Results
Recruitment
Baseline data
Minoxidil | Placebo | ||
---|---|---|---|
N Total | N | N | |
Male | 12 | 4 | 8 |
Age group 6-11 | 7 | 2 | 5 |
Age group 12-18 | 5 | 2 | 3 |
Female | 9 | 5 | 4 |
Age group 6-11 | 4 | 1 | 3 |
Age group 12-18 | 5 | 4 | 1 |
History of hypertension | 21 | 2 | 2 |
Age group 6-11 | 11 | 0 | 2 |
Age group 12-18 | 10 | 2 | 0 |
Concomitant Treatment | 21 | 3 | 4 |
History of cardiovascular disease | 21 | 4 | 6 |
Mean systolic blood pressure mmHg | 21 | 128 (17)* | 121 (13) |
Mean diastolic blood pressure mm Hg | 21 | 78 (16)* | 73 (9)* |
Numbers analysed
Outcomes and estimation
Minoxidil | Placebo | ||||||
---|---|---|---|---|---|---|---|
mean | (95% CI) | mean | (95% CI) | ICC | p value | ||
CCA | IMT (mm) | 0.03 | (-0.002 ; 0.06) | 0.01 | (-0.02 ; 0.04) | 0.86 | 0.4 |
diameter (mm) | 0.41 | (0.26 ; 0.56) | 0.05 | (-0.08 ; 0.19) | 0.56 | 0.0006 | |
distensibility (%) | 1.1 | (-2.3 ; 4.4) | 2.9 | (-0.2 ; 6) | 0.90 | 0.4 | |
RHA | IMT (mm) | -0.04 | (-0.08 ; 0.01) | -0.06 | (-0.10 ; -0.02) | 0.66 | 0.4 |
diameter (mm) | 0.02 | (-0.15 ; 0.19) | -0.23 | (-0.37 ; -0.08) | 0.63 | 0.03 | |
distensibility (%) | -1.1 | (-8.5 ; 6.4) | 1.8 | (-4.8 ; 8.4) | 0.01 | 0.6 | |
mean | (SD) | mean | (SD) | ||||
PWV | (m/s) | -0.8 | (2.0) | -1.5 | (3.0) | 0.7 | |
24-H mean SBP (mmHg) | 3.6 | (8.7) | 0.8 | (7.1) | 0.5 | ||
24-H mean DBP (mmHg) | 1.6 | (7.9) | 0.9 | (4.7) | 0.6 |
Minoxidil | Placebo | |||||
---|---|---|---|---|---|---|
mean | (IC95%) | mean | (IC95%) | p value | ||
CCA | IMT (mm) | 0.07 | (0.04 ; 0.10) | 0.01 | (-0.02 ; 0.04) | 0.008 |
distensibility (%) | 0.2 | (-3.2 ; 3.5) | 6.3 | (3.3 ; 9.2) | 0.008 | |
Right humeral artery | IMT (mm) | 0.01 | (-0.04 ; 0.06) | -0.06 | (-0.11 ; -0.01) | 0.04 |
distensibility (%) | -1.4 | (-9.1 ; 6.4) | -4.9 | (-11.7 ; 1.9) | 0.5 |
N | minoxidil | N | placebo | |
---|---|---|---|---|
Withdrawal from treatment | 9 | 1 | 12 | 0 |
Withdrawal from treatment because of adverse events | 9 | 1 | 12 | 0 |
Serious Adverse events* | 9 | 1 | 12 | 1 |
Any adverse events | 9 | 8 | 12 | 11 |
Hypertrichosis | 9 | 5 | 12 | 0 |